Estudio de las alteraciones de la inmunidad celular en pacientes sometidos a distintas terapias biológicas utilizadas en el trasplante

Abstract

Administration of therapeutic agents against the immune response that is triggered after solid organ trasplantation (SOT), includes monoclonal antibodies (anti IL2R o anti CD25) and other polyclonal antibodies (antithymocyte or antilymphocyte globulins) are used in the induction phase. In the peri-transplant period, other agents such as corticosteroids, calcineurin inhibitors (CNI) and mTOR inhibitors are also administered sequentially and progressively. These drugs reduce the response to the graft, but also increase the risk of infections and neoplasms. The effectiveness of the two-dose immunosuppression regimen of basiliximab (BAS) was initially determined in kidney transplant recipients, and its use was transferred to other types of TOS, conferring immunoprophylaxis between 4 to 6 weeks. It is currently unknown whether a single dose is correlated with shorter duration and greater complications in post-CT (heart transplantation). There are no studies that compare the different kinetics of CD25 expression in different subpopulations of T lymphocytes for both anti-CD25 antibodies...